These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26535126)

  • 1. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response.
    Tack J; Lappalainen J; Diva U; Tummala R; Sostek M
    United European Gastroenterol J; 2015 Oct; 3(5):471-80. PubMed ID: 26535126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
    Lawson R; King F; Marsh K; Altincatal A; Cimen A
    Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
    Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K
    Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies.
    Chey WD; Brenner DM; Cash BD; Hale M; Adler J; Jamindar MS; Rockett CB; Almenoff JS; Bortey E; Gudin J
    J Pain Res; 2023; 16():2943-2953. PubMed ID: 37664485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naloxegol for opioid-induced constipation in patients with noncancer pain.
    Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
    N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
    Webster L; Diva U; Tummala R; Sostek M
    Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating Clinical Findings into the Patient's Perspective: Post-hoc Pooled Analysis of Bowel Movement Changes as a Predictor of Improvement in Patients' Opioid-induced Constipation Symptoms and Outcomes.
    Coyne KS; Poon JL; Thompson C; Hu Y; Datto CJ; Sostek M
    Clin Ther; 2017 Jan; 39(1):75-88. PubMed ID: 27938897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
    Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
    J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
    Webster L; Tummala R; Diva U; Lappalainen J
    J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxegol , a new drug for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxegol for the treatment of opioid-induced constipation.
    Tack J; Corsetti M
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
    Leonard J; Baker DE
    Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
    Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
    Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB; Kowey P; Diva U; Sostek M; Tummala R
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.
    Lemaire A; Pointreau Y; Narciso B; Piloquet FX; Braniste V; Sabaté JM
    Support Care Cancer; 2021 Dec; 29(12):7577-7586. PubMed ID: 34120247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
    Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
    CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.